PMID- 15256423
OWN - NLM
STAT- MEDLINE
DCOM- 20041223
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 104
IP  - 10
DP  - 2004 Nov 15
TI  - Better outcome of adult acute lymphoblastic leukemia after early genoidentical 
      allogeneic bone marrow transplantation (BMT) than after late high-dose therapy 
      and autologous BMT: a GOELAMS trial.
PG  - 3028-37
AB  - Various transplantation strategies have been designed to improve the poor 
      prognosis of adult (ages 15 to 60 years) acute lymphoblastic leukemia (ALL). The 
      GOELAL02 trial evaluated the impact of early allogeneic bone marrow 
      transplantation (alloBMT) or delayed unpurged autologous stem cell 
      transplantation (ASCT) for patients who had no human leukocyte antigen 
      (HLA)-matched sibling donor or who were older than 50 years. Inclusion criteria 
      included at least one of the following: age older than 35 years; non-T-ALL; 
      leukocytosis greater than 30 x 10(9)/L; t(9;22), t(4;11), or t(1; 19); or failure 
      to achieve complete remission (CR) after one induction course. Among 198 
      patients, the median age was 33 years. The CR rate was 80% with vincristine, 
      idarubicine, L-asparaginase, and randomized intravenous injection or oral 
      steroids (P = nonsignificant [ns]). AlloBMT was performed after 2 consolidation 
      courses while ASCT was delayed after 1 additional reinduction. Intensified 
      conditioning regimen before transplantation included etoposide, cyclophosphamide, 
      and total body irradiation (TBI). Median follow-up was 5.1 years. The median 
      overall survival (OS) was 29 months, with a 6-year OS of 41%. On an 
      intent-to-treat analysis for patients younger than 50 years, alloBMT 
      significantly improved the 6-year OS (75% versus 40% after ASCT; P = .0027). 
      Randomized interferon-alpha maintenance had no effect on relapse or survival 
      after ASCT. In conclusion, the outcome of adult ALL is better after early alloBMT 
      than after delayed ASCT.
FAU - Hunault, Mathilde
AU  - Hunault M
AD  - Hematology Department, University of Angers, France.
FAU - Harousseau, Jean-Luc
AU  - Harousseau JL
FAU - Delain, Martine
AU  - Delain M
FAU - Truchan-Graczyk, Malgorzata
AU  - Truchan-Graczyk M
FAU - Cahn, Jean-Yves
AU  - Cahn JY
FAU - Witz, Francis
AU  - Witz F
FAU - Lamy, Thierry
AU  - Lamy T
FAU - Pignon, Bernard
AU  - Pignon B
FAU - Jouet, Jean-Pierre
AU  - Jouet JP
FAU - Garidi, Reda
AU  - Garidi R
FAU - Caillot, Denis
AU  - Caillot D
FAU - Berthou, Christian
AU  - Berthou C
FAU - Guyotat, Denis
AU  - Guyotat D
FAU - Sadoun, Alain
AU  - Sadoun A
FAU - Sotto, Jean-Jacques
AU  - Sotto JJ
FAU - Lioure, Bruno
AU  - Lioure B
FAU - Casassus, Philippe
AU  - Casassus P
FAU - Solal-Celigny, Philippe
AU  - Solal-Celigny P
FAU - Stalnikiewicz, Laure
AU  - Stalnikiewicz L
FAU - Audhuy, Bruno
AU  - Audhuy B
FAU - Blanchet, Odile
AU  - Blanchet O
FAU - Baranger, Laurence
AU  - Baranger L
FAU - Bene, Marie-Christine
AU  - Bene MC
FAU - Ifrah, Norbert
AU  - Ifrah N
CN  - GOELAMS (Groupe Ouest-Est des Leucemies Airgues et Maladies du Sang) Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20040715
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interferon-alpha)
RN  - 5J49Q6B70F (Vincristine)
RN  - 86189-66-4 (idarubicinol)
RN  - EC 3.5.1.1 (Asparaginase)
RN  - ZS7284E0ZP (Daunorubicin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Agents/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Asparaginase/administration & dosage
MH  - *Bone Marrow Transplantation
MH  - Combined Modality Therapy
MH  - Daunorubicin/administration & dosage/*analogs & derivatives
MH  - Humans
MH  - Interferon-alpha/administration & dosage
MH  - Middle Aged
MH  - Philadelphia Chromosome
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics/mortality/*therapy
MH  - Prognosis
MH  - Remission Induction
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - Vincristine/administration & dosage
EDAT- 2004/07/17 05:00
MHDA- 2004/12/24 09:00
CRDT- 2004/07/17 05:00
PHST- 2004/07/17 05:00 [pubmed]
PHST- 2004/12/24 09:00 [medline]
PHST- 2004/07/17 05:00 [entrez]
AID - S0006-4971(20)55855-2 [pii]
AID - 10.1182/blood-2003-10-3560 [doi]
PST - ppublish
SO  - Blood. 2004 Nov 15;104(10):3028-37. doi: 10.1182/blood-2003-10-3560. Epub 2004 
      Jul 15.